#ACC26: Merck leans toward lower Winrevair dose in Phase 3 trial for rare form of heart failure
#ACC26: Merck leans toward lower Winrevair dose in Phase 3 trial for rare form of heart failure
Body unavailable. Use the original source.
#ACC26: Merck leans toward lower Winrevair dose in Phase 3 trial for rare form of heart failure
A compact weekly email covering company moves, product signals, regulatory updates, and notable funding.